Valuation: Alector, Inc.

Market Cap 232M 207M 193M 176M 331M 22.48B 333M 2.32B 910M 11.46B 872M 853M 36.77B P/E 2026 *
-2.47x
P/E 2027 * -3.15x
Enterprise Value -62.24M -55.58M -51.71M -47.03M -88.8M -6.02B -89.18M -622M -244M -3.07B -234M -229M -9.85B EV / Sales 2026 *
-2.68x
EV / Sales 2027 * -2.54x
Free-Float
90.47%
Yield 2026 *
-
Yield 2027 * -
1 day+2.97%
1 week+14.92%
Current month+12.43%
1 month-2.80%
3 months+29.19%
6 months-15.10%
Current year+33.33%
1 week 1.73
Extreme 1.73
2.23
1 month 1.73
Extreme 1.73
2.73
Current year 1.37
Extreme 1.37
2.76
1 year 1.09
Extreme 1.09
3.4
3 years 0.87
Extreme 0.87
8.9
5 years 0.87
Extreme 0.87
27
10 years 0.87
Extreme 0.87
43.32
Manager TitleAgeSince
Chief Executive Officer 71 01/05/2013
Director of Finance/CFO 52 20/06/2025
Chief Tech/Sci/R&D Officer - 01/01/2017
Director TitleAgeSince
Director/Board Member 71 01/05/2013
Director/Board Member 72 01/10/2018
Chairman 77 13/06/2023
Date Insider Type Main position Quantity % Market Cap. Importance
04/09/26 Sell

Controller/Auditor

-3,625 0.0032%
03/09/26 Sell

Chief Financial Officer

-29,251 0.0262%
03/09/26 Sell

Founder

-72,606 0.0650%
Change 5-day change 1-year change 3-year change Capi.($)
+2.97%+14.92%-31.13%-66.88% 232M
-2.59%-5.70%+50.69%+79.01% 70.61B
+3.23%-10.67%+6.27%+53.48% 51.01B
+1.56%+1.17%+8.49%+32.39% 48.1B
+0.39%+0.65%+31.14%+27.04% 42.78B
+0.87%-8.17%+293.37%+643.87% 40.67B
+1.24%-1.01%+10.74%+94.55% 40.3B
-2.13%-1.64%+8.63%+46.15% 30.59B
-0.46%-1.28%+42.23%+14.70% 28.16B
+5.32%+0.06%-5.00%-12.60% 24.36B
Average +1.04%-0.90%+41.54%+91.17% 37.68B
Weighted average by Cap. +0.56%-2.93%+51.30%+112.85%

Financials

2026 *2027 *
Net sales 23.22M 20.74M 19.29M 17.55M 33.13M 2.25B 33.27M 232M 90.97M 1.15B 87.2M 85.29M 3.68B 28.97M 25.87M 24.07M 21.89M 41.33M 2.8B 41.51M 290M 113M 1.43B 109M 106M 4.59B
Net income -104M -92.54M -86.09M -78.3M -148M -10.03B -148M -1.04B -406M -5.11B -389M -381M -16.41B -97.35M -86.94M -80.88M -73.56M -139M -9.42B -139M -973M -381M -4.8B -366M -358M -15.41B
Net Debt -294M -263M -245M -223M -420M -28.5B -422M -2.94B -1.15B -14.53B -1.11B -1.08B -46.63B -306M -273M -254M -231M -436M -29.6B -438M -3.06B -1.2B -15.09B -1.15B -1.12B -48.43B
Projected Income Statement - Annual - Alector, Inc.
Logo Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Employees
103
Date Price Change Volume
09/10/26 $2.080 +2.97% 3,118,490
08/10/26 $2.020 +5.21% 6,453,307
07/10/26 $1.920 +6.08% 3,972,727
06/10/26 $1.810 -9.05% 10,177,269
05/10/26 $1.990 +9.94% 89,983,690
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Ratings Surperformance© - Alector, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
2.080USD
Average target price
3.300USD
Spread / Average Target
+58.65%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alector, Inc.
  1. Stock Market
  2. Stocks
  3. ALEC Stock